Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

Clinical trial NCT05614453 · WITHDRAWN

Trial details

NCT number: NCT05614453
Sponsor: Australia New Zealand Gynaecological Oncology Group
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Cervical Cancer

Start date: 2023-06-01
Primary completion: 2023-06-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.